← Leaderboards
M Melissa Gilbert
Emory University
$2,580,976
Attributed
$5,265,305
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–22$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,265,305 · 4
By mechanism
R01$4,530,668 · 2
P30$639,865 · 1
F32$94,772 · 1
Top collaborators
- Adam I Marcus13 shared
- Wei Zhou5 shared
Most similar at Emory University
Same institution · by research overlap
- Adam I Marcus$15,360,223
- Yong Wan$11,312,987
- Kenneth H Moberg$7,741,465
- Haian Fu$16,783,892
- Melissa Ann Brown$7,601,690
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorCellsMalignant Neoplasm Of LungIn VitroCancer CellIn VivoNeoplasm MetastasisSignal TransductionMouse ModelGeneticPhenotype3-DimensionalAnimal ModelPathway InteractionsGenesMutationCell PolarityMutantCell AdhesionGenetically Engineered MouseKras2 GeneFocal Adhesion Kinase 1Monitor
Grant awards (23)
Cancer Animal Models$102,723
P30 · FY2022 · CA · contact PI
Cancer Animal Models$100,826
P30 · FY2021 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$506,871
R01 · FY2020 · CA
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$356,850
R01 · FY2020 · CA
Cancer Animal Models$100,826
P30 · FY2020 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$491,665
R01 · FY2019 · CA
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$345,265
R01 · FY2019 · CA
Cancer Animal Models$100,826
P30 · FY2019 · CA · contact PI
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$96,427
R01 · FY2019 · CA
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$506,871
R01 · FY2018 · CA
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$355,821
R01 · FY2018 · CA
Cancer Animal Models$100,826
P30 · FY2018 · CA · contact PI
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$99,409
R01 · FY2018 · CA
Cancer Animal Models$13,365
P30 · FY2018 · CA · contact PI
Cancer Animal Models$4,861
P30 · FY2018 · CA · contact PI
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$504,281
R01 · FY2017 · CA
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$369,821
R01 · FY2017 · CA
Cancer Animal Models$115,612
P30 · FY2017 · CA · contact PI
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1$36,256
R01 · FY2017 · CA
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients$504,281
R01 · FY2016 · CA
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer$356,850
R01 · FY2016 · CA
Drosophila Tsg101: Coordination of growth control and epithelial polarity$48,796
F32 · FY2007 · GM · contact PI
Drosophila Tsg101: Coordination of growth control and epithelial polarity$45,976
F32 · FY2006 · GM · contact PI